Molecular monitoring of chronic myeloid leukaemia (CML) patients by real time quantitative reverse transcriptase PCR (RQ-PCR) is of clinical value, but the use of diverse laboratory protocols and units of measurement make it difficult to compare results between and sometimes within centres. This review explores the intrinsic difficulties in standardising the RQ-PCR analysis, summarises the progress that has been made following the proposal for a new International Scale for BCR-ABL measurement and discusses how further improvements are likely to be made.<br/
: Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kin...
Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia....
Objective: Quantification of the BCR-ABL transcript is recommended to follow-up CML patients that tr...
Molecular monitoring for patients with chronic myeloid leukaemia (CML) has become an important pract...
The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients treated with ...
Sequential measurement of BCR-ABL1 mRNA levels by reverse transcription quantitative polymerase chai...
The pathognomonic genetic alteration in CML is the formation of the BCR-ABL fusion gene, which produ...
Serial quantification of BCR-ABL1 messenger RNA (mRNA) is an important therapeutic indicator for pat...
P>Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain react...
We have developed a rapid real-time quantitative PCR method for measuring BCR-ABL mRNA levels in per...
The BCR-ABL1 fusion, resulting from the reciprocal translocation t(9;22)(q34;q11), produces a consti...
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid ...
The pathognomonic genetic alteration in chronic myeloid leukemia is the formation of the BCR-ABL1 fu...
For patients with chronic myeloid leukaemia (CML), treatment guidelines recommend monitoring respons...
Molecular pathogenesis of chronic myeloid leukemia (CML) is well established and molecular monitori...
: Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kin...
Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia....
Objective: Quantification of the BCR-ABL transcript is recommended to follow-up CML patients that tr...
Molecular monitoring for patients with chronic myeloid leukaemia (CML) has become an important pract...
The BCR-ABL1 translocation is a hallmark of chronic myeloid leukemia. Because patients treated with ...
Sequential measurement of BCR-ABL1 mRNA levels by reverse transcription quantitative polymerase chai...
The pathognomonic genetic alteration in CML is the formation of the BCR-ABL fusion gene, which produ...
Serial quantification of BCR-ABL1 messenger RNA (mRNA) is an important therapeutic indicator for pat...
P>Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain react...
We have developed a rapid real-time quantitative PCR method for measuring BCR-ABL mRNA levels in per...
The BCR-ABL1 fusion, resulting from the reciprocal translocation t(9;22)(q34;q11), produces a consti...
Standardized monitoring of BCR::ABL1 mRNA levels is essential for the management of chronic myeloid ...
The pathognomonic genetic alteration in chronic myeloid leukemia is the formation of the BCR-ABL1 fu...
For patients with chronic myeloid leukaemia (CML), treatment guidelines recommend monitoring respons...
Molecular pathogenesis of chronic myeloid leukemia (CML) is well established and molecular monitori...
: Measurement of BCR activator of RhoGEF and GTPase -ABL proto-oncogene 1, non-receptor tyrosine kin...
Molecular monitoring is a key component of the management of patients with chronic myeloid leukemia....
Objective: Quantification of the BCR-ABL transcript is recommended to follow-up CML patients that tr...